Drug intelligence / Profile preview

Credelio Quattro

Development stage
Unknown
Lead developer
Elanco
Modality
Small Molecules
Administration
Oral
01

Overview

Credelio Quattro is a veterinary combination drug formulated as a monthly chewable tablet for dogs and puppies. It provides broad-spectrum protection against six major types of parasites, including fleas, ticks, heartworm disease, roundworms, hookworms, and tapeworms. The product contains four active ingredients—lotilaner (an isoxazoline ectoparasiticide), moxidectin (a macrocyclic lactone endectocide), praziquantel (an anthelmintic effective against cestodes), and pyrantel (a tetrahydropyrimidine anthelmintic effective against nematodes). Lotilaner acts by inhibiting GABA-gated chloride channels in arthropods leading to paralysis and death of fleas and ticks. Moxidectin interferes with neurotransmission in nematodes and prevents heartworm disease by targeting Dirofilaria immitis larvae. Praziquantel increases the permeability of cell membranes to calcium ions in tapeworms causing paralysis and death. Pyrantel acts as a depolarizing neuromuscular blocking agent on susceptible intestinal worms such as roundworms and hookworms[1][2][3][7]. The product is approved for use in dogs 8 weeks of age or older weighing at least 3.3 pounds.

Brand names
Credelio Quattro
02

Targets

CaV (Voltage-gated calcium channel protein complex)GABAA (Gamma-aminobutyric acid receptor)Nicotinic Acetylcholine ReceptorGluCl (Glutamate-gated chloride channel)

Beyond the preview

Go deeper on Credelio Quattro.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Credelio Quattro.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call